Centessa Pharmaceuticals (CNTA) Stock Forecast, Price Target & Predictions
CNTA Stock Forecast
Centessa Pharmaceuticals stock forecast is as follows: an average price target of $21.67 (represents a 36.38% upside from CNTA’s last price of $15.89) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
CNTA Price Target
The average price target for Centessa Pharmaceuticals (CNTA) is $21.67 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $19.00. This represents a potential 36.38% upside from CNTA's last price of $15.89.
CNTA Analyst Ratings
According to 8 Wall Street analysts, Centessa Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CNTA stock is 0 'Strong Buy' (0.00%), 6 'Buy' (75.00%), 2 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Centessa Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Jeffrey Hung | Morgan Stanley | $26.00 | $15.85 | 64.04% | 63.62% |
| Sep 11, 2024 | Kelly Shi | Jefferies | $19.00 | $14.99 | 26.75% | 19.57% |
| Sep 10, 2024 | Kostas Biliouris | BMO Capital | $20.00 | $16.02 | 24.84% | 25.87% |
| Aug 14, 2024 | Kostas Biliouris | BMO Capital | $15.00 | $12.60 | 19.05% | -5.60% |
The latest Centessa Pharmaceuticals stock forecast, released on Sep 19, 2024 by Jeffrey Hung from Morgan Stanley, set a price target of $26.00, which represents a 64.04% increase from the stock price at the time of the forecast ($15.85), and a 63.62% increase from CNTA last price ($15.89).
Centessa Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 4 |
| Avg Price Target | - | $20.00 | $20.00 |
| Last Closing Price | $15.89 | $15.89 | $15.89 |
| Upside/Downside | -100.00% | 25.87% | 25.87% |
In the current month, the average price target of Centessa Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Centessa Pharmaceuticals's last price of $15.89. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Sep 18, 2024 | B. Riley | - | Buy | Initialise |
| Sep 11, 2024 | Jefferies | Buy | Buy | Hold |
| Sep 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 09, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Aug 14, 2024 | BMO Capital | Outperform | Outperform | Hold |
| Jul 18, 2024 | Oppenheimer | - | Outperform | Initialise |
| Jun 21, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 12, 2022 | Morgan Stanley | Overweight | Underweight | Downgrade |
| Aug 12, 2022 | Morgan Stanley | - | Overweight | Downgrade |
Centessa Pharmaceuticals's last stock rating was published by Morgan Stanley on Sep 19, 2024. The company Upgrade its CNTA rating from "Equal-Weight" to "Overweight".
Centessa Pharmaceuticals Financial Forecast
Centessa Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CNTA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Centessa Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict CNTA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Centessa Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Centessa Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-43.80M | $-43.80M | $-47.63M | $-44.89M | $-47.76M | $-43.39M | $-42.39M |
| High Forecast | $-43.80M | $-43.80M | $-47.63M | $-44.89M | $-47.76M | $-40.29M | $-42.39M |
| Low Forecast | $-43.80M | $-43.80M | $-47.63M | $-44.89M | $-47.76M | $-45.45M | $-42.39M |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CNTA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Centessa Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Centessa Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CNTA last annual SG&A of $NaN (undefined).
Centessa Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.40 | $-0.40 | $-0.43 | $-0.41 | $-0.44 | $-0.40 | $-0.39 |
| High Forecast | $-0.40 | $-0.40 | $-0.43 | $-0.41 | $-0.44 | $-0.37 | $-0.39 |
| Low Forecast | $-0.40 | $-0.40 | $-0.43 | $-0.41 | $-0.44 | $-0.42 | $-0.39 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Centessa Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CNTA previous annual EPS of $NaN (undefined).
Centessa Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| IPSC | Century Therapeutics | $1.26 | $20.00 | 1487.30% | Buy |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
| LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
| ERAS | Erasca | $2.87 | $7.00 | 143.90% | Buy |
| GNFT | Genfit | $5.76 | $13.00 | 125.69% | Buy |
| MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
| CCCC | C4 Therapeutics | $6.45 | $13.50 | 109.30% | Buy |
| CGEM | Cullinan Oncology | $15.92 | $31.50 | 97.86% | Buy |
| DSGN | Design Therapeutics | $5.32 | $9.67 | 81.77% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
| TARS | Tarsus Pharmaceuticals | $46.21 | $62.00 | 34.17% | Buy |
| EWTX | Edgewise Therapeutics | $34.48 | $45.00 | 30.51% | Buy |
| CRNX | Crinetics Pharmaceuticals | $56.82 | $70.14 | 23.44% | Buy |
| NUVL | Nuvalent | $89.53 | $107.83 | 20.44% | Buy |
| IRON | Disc Medicine | $58.25 | $66.86 | 14.78% | Buy |
| TRDA | Entrada Therapeutics | $17.77 | $18.00 | 1.29% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
CNTA Forecast FAQ
Is Centessa Pharmaceuticals a good buy?
Yes, according to 8 Wall Street analysts, Centessa Pharmaceuticals (CNTA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 6 'Buy' recommendations, accounting for 75.00% of CNTA's total ratings.
What is CNTA's price target?
Centessa Pharmaceuticals (CNTA) average price target is $21.67 with a range of $19 to $26, implying a 36.38% from its last price of $15.89. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Centessa Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for CNTA stock, the company can go up by 36.38% (from the last price of $15.89 to the average price target of $21.67), up by 63.62% based on the highest stock price target, and up by 19.57% based on the lowest stock price target.
Can Centessa Pharmaceuticals stock reach $20?
CNTA's average twelve months analyst stock price target of $21.67 supports the claim that Centessa Pharmaceuticals can reach $20 in the near future.
What are Centessa Pharmaceuticals's analysts' financial forecasts?
Centessa Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-134M (high $-130M, low $-136M), average SG&A $0 (high $0, low $0), and average EPS is $-1.22 (high $-1.191, low $-1.239). CNTA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-180M (high $-180M, low $-180M), average SG&A $0 (high $0, low $0), and average EPS is $-1.645 (high $-1.645, low $-1.645).